<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-921-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GANFORT EYE DROPS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOLOL MALEATE,BIMATOPROST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,0.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALLERGAN PHARMACEUTICALS LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALLERGAN PHARMACEUTICALS LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01EE03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        S01ED01
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>GANFORT contains two different active substances (bimatoprost and timolol) that both reduce pressure in the eye. Bimatoprost belongs to a group of medicines called prostamides, a prostaglandin analogue. Timolol belongs to a group of medicines called beta-blockers.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid is constantly being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up and could eventually damage your sight (an illness called glaucoma). GANFORT works by reducing the production of liquid and also increasing the amount of liquid that is drained. This reduces the pressure inside the eye.</p><p>&nbsp;</p><p>GANFORT eye drops are used to treat high pressure in the eye in adults, including the elderly<strong>. </strong>This high pressure can lead to glaucoma. Your doctor will prescribe you GANFORT when other eye drops containing beta-blockers or prostaglandin analogues&nbsp; have not worked sufficiently on their own.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use GANFORT eye drops, solution</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to bimatoprost, timolol, beta-blockers or any of the other ingredients of GANFORT (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have now or have had in past respiratory problems such as asthma, severe chronic obstructive bronchitis (severe lung disease which may cause wheeziness, difficulty in breathing and/ or long-standing cough)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems such as low heart rate, heart block, or heart failure</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Before you use this medicine, tell your doctor if you have now or have had in the past</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, low blood pressure,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbances of heart rate such as slow heart beat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems, asthma or chronic obstructive pulmonary disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor blood circulation disease (such as Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome)</p><p>-&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; overactivity of the thyroid gland as timolol may mask signs and symptoms of</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; thyroid disease</p><p>-&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; diabetes as timolol may mask signs and symptoms of&nbsp; low blood sugar</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver or kidney problems</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye surface problems</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; separation of one of the layers within the eyeball after surgery to reduce the pressure in the eye</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; known risk factors for macular oedema (swelling of the retina within the eye leading to worsening vision), for example, cataract surgery</p><p>&nbsp;</p><p>Tell your doctor before surgical anaesthesia that you are using GANFORT as timolol may change effects of some medicines used during anaesthesia.</p><p>GANFORT may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too. The colour of your iris may also go darker over time.&nbsp; These changes may be permanent. The change may be more noticeable if you are only treating one eye. GANFORT may cause hair growth when in contact with the skin surface.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>GANFORT should not be used in children and teenagers under 18.</p><p>&nbsp;</p><p><strong>Other medicines and GANFORT</strong></p><p>GANFORT can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma. Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor if you are using or intend to use medicines to lower blood pressure, heart medicine, medicines to treat diabetes, quinidine (used to treat heart conditions and some types of malaria) or medicines to treat depression known as fluoxetine and paroxetine.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding&nbsp; </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not use GANFORT if you are pregnant unless your doctor still recommends it.</p><p>&nbsp;</p><p>Do not use GANFORT if you are breast-feeding. Timolol may get into your breast milk.</p><p>Ask your doctor for advice before taking any medicine during breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>GANFORT may cause blurred vision in some patients. Do not drive or use machines until the symptoms have cleared.</p><p><strong>&nbsp;</strong></p><p><strong>GANFORT contains Benzalkonium chloride</strong></p><p>Ganfort contains a preservative called benzalkonium chloride.</p><p>This medicine contains 0.15 mg benzalkonium chloride in each 3 ml of solution which is equivalent to 0.05 mg/ml.</p><p>Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards.</p><p>Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use GANFORT exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The usual dose is one drop once a day, either in the morning or in the evening in each eye that needs treatment. &nbsp;Use at the same time each day.</p><p>&nbsp;</p><p><strong>Instructions for use</strong></p><p>You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first use it.</p><p>&nbsp;</p><p><img alt="" width="540" height="226" src="data:image/png;base64,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" /></p><p><strong>5.<img alt="" width="300" height="125" src="data:image/png;base64,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" /></strong></p><p>. Wash your hands. Tilt your head back and look at the ceiling.</p><p>2. Gently pull down the lower eyelid until there is a small pocket.</p><p>3. Turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment.</p><p>4. Let go of the lower lid, and close your eye..</p><p>5. Whilst keeping the eye closed, press your finger against the corner of the closed eye (the site where the eye meets the nose) and hold for 2 minutes. This helps to stop GANFORT getting into the rest of the body.</p><p>&nbsp;</p><p>If a drop misses your eye, try again.</p><p>&nbsp;</p><p>To avoid contamination, do not let the tip of the bottle touch your eye or anything else. Put the cap back on and close the bottle straight after you have used it.</p><p>&nbsp;</p><p>If you use GANFORT with another eye medicine, leave at least 5 minutes between putting in GANFORT and the other medicine. Use any eye ointment or eye gel last.</p><p>&nbsp;</p><p><strong>If you use more GANFORT than you should</strong></p><p>If you use more GANFORT than you should, it is unlikely to cause you any serious harm. Put your next dose in at the usual time. If you are worried, talk to your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to use GANFORT</strong></p><p>If you forget to use GANFORT, use a single drop as soon as you remember, and then go back to your regular routine. Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using GANFORT</strong></p><p>GANFORT should be used every day to work properly.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, GANFORT can cause side effects, although not everybody gets them.&nbsp; You can usually carry on taking the drops, unless the effects are serious. If you&rsquo;re worried, talk to a doctor or pharmacist. Do not stop using Ganfort without speaking to your doctor.</p><p>&nbsp;</p><p>The following side effects may be seen with GANFORT (multi-dose and/or single dose):</p><p>&nbsp;</p><p><strong>Very common side effects</strong></p><p>These may affect more than 1 user in 10</p><p><u>Affecting the eye</u></p><p>redness.</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect 1 to 9 users in 100</p><p><u>Affecting the eye</u></p><p>burning, itching, stinging, irritation of the conjunctiva (see-through layer of the eye), sensitivity to light, eye pain, sticky eyes, dry eyes, a feeling of something in the eye, small breaks in the surface of the eye with or without inflammation, difficulty in seeing clearly, redness and itching of the eyelids, hair growing around the eye, darkening of the eyelids, darker skin colour around the eyes, longer eyelashes, eye irritation, watery eyes, swollen eyelids, reduced vision.</p><p>&nbsp;</p><p><u>Affecting other parts of the body</u></p><p>runny nose, headache.</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect 1 to 9 users in 1,000</p><p><u>Affecting the eye</u></p><p>abnormal sensation in the eye, iris inflammation, swollen conjunctiva (see-through layer of the eye), painful eyelids, tired eyes, in-growing eyelashes, darkening of iris colour, eyes appear sunken, eyelid drooping, eyelid shrinking, (moving away from the surface of the eye leading to incomplete closure of the eyelids), skin tightness of the eyelids, darkening of eyelashes&nbsp; .</p><p>&nbsp;</p><p><u>Affecting other parts of the body</u></p><p>shortness of breath.</p><p>&nbsp;</p><p><strong>Side effects where the frequency is not known </strong></p><p><u>Affecting the eye</u></p><p>cystoid macular oedema (swelling of the retina within the eye leading to worsening vision), eye swelling, blurred vision , ocular discomfort.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Affecting other parts of the body</u></p><p>difficulty breathing / wheezing, symptoms of allergic reaction (swelling, redness of the eye and rash of the skin), changes in your taste sensation, dizziness, slowing of heart rate, high blood pressure, &nbsp;difficulty sleeping, nightmare, asthma, hair loss, skin discolouration (periocular), &nbsp;tiredness.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Additional side effects have been seen in patients using eye drops containing timolol or bimatoprost and so may possibly be seen with GANFORT. Like other medicines applied into eyes, timolol is absorbed into the blood. This may cause similar side effects as seen with &rdquo;intravenous&rdquo; and /or &ldquo;oral&rdquo; beta-blocking agents. The chance of having side effects after using eye drops is lower than when medicines are for example, taken by mouth or injected. Listed side effects include reactions seen within the bimatoprost and timolol when used for treating eye conditions:</p><ul><li>Severe allergic reactions with swelling and difficulty breathing which could be life-threatening</li><li>Low blood sugar</li><li>Depression; memory loss, hallucination.</li><li>Fainting; stroke; decreased blood flow to the brain; worsening of myasthenia gravis (increased muscle weakness); tingling sensation</li><li>Decreased sensation of your eye surface; double vision; drooping eyelid; separation of one of the layers within the eyeball after surgery to reduce the pressure in the eye; inflammation of the surface of the eye, bleeding in the back of the eye (retinal bleeding), inflammation within the eye, increased blinking.</li><li>Heart failure; irregularity or stopping of the heartbeat; slow or fast heartbeat; too much fluid, mainly water, accumulating in the body; chest pain</li><li>Low blood pressure, swelling or coldness of your hands, feet and extremities, caused by constriction of your blood vessels</li><li>Cough, worsening of asthma, worsening of the lung disease called chronic obstructive pulmonary disease (COPD)</li><li>Diarrhoea; stomach pain; feeling and being sick; indigestion; dry mouth</li><li>Red scaly patches on skin; skin rash</li><li>Muscle pain</li><li>Reduced sexual urge; sexual dysfunction</li><li>Weakness</li><li>An increase in blood test results that show how your liver is working</li></ul><p>&nbsp;</p><p>&nbsp;</p><p>Other side effects reported with eye drops containing phosphates</p><p>&nbsp;</p><p>This medicine contains 2.85 mg phosphates in each 3 ml of solution which is equivalent to 0.95 mg/ml. If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment</p><p>&nbsp;</p><p><u>Reporting of side effects</u></p><p>If any of the side effects gets serious, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.&nbsp; You can also report side effects directly via the national reporting system listed in 6 .</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep GANFORT out of the sight and reach of children.</p><p>Store at or below 25&deg;C</p><p>&nbsp;</p><p>Do not use GANFORT after the expiry date which is stated on the bottle label and the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>&nbsp;</p><p>Once opened, solutions may become contaminated, which can cause eye infections. Therefore, you must throw away the bottle 4 weeks after you first opened it, even if some solution is left. To help you remember, write down the date that you opened it in the space on the carton.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are bimatoprost&nbsp;0.3&nbsp;mg/ml and timolol 5&nbsp;mg/ml corresponding to timolol maleate 6.8&nbsp;mg/ml.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are benzalkonium chloride (a preservative), sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water. Small amounts of hydrochloric acid or sodium hydroxide may be added to bring the solution to the correct pH (acidity) level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GANFORT is a colourless to slightly yellow, clear eye drop solution in a plastic bottle. Each pack contains either 1 or 3 plastic bottles each with a screw-cap. Each bottle is about half full and contains 3 millilitres of solution. This is enough for 4 weeks’ usage. Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong></p><p>Allergan Pharmaceuticals Ireland</p><p>Castlebar Road</p><p>Westport</p><p>Co. Mayo</p><p>Ireland</p><p><strong>Marketing Authorization Holder</strong></p><p>AbbVie Deutschland GmbH &amp; Co. KG</p><p>Knollstrasse</p><p>67061 Ludwigshafen</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	
	This leaflet was last revised in  January 2022



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي جانفورت على مادتين فعالتين مختلفتين (بيماتوبروست، وتيمولول) وكلاهما يخفض الضغط في العين. ينتمي بيماتوبروست إلى مجموعة من الأدوية تُسمى البروستاميدات، وهو أحد محاكيات البروستاجلاندين. وينتمي تيمولول إلى مجموعة من الأدوية تُسمى حاصرات البيتا.</p><p dir="RTL">تحتوي عينك على سائل مائي رائق يغذي العين من الداخل. هذا السائل يتم صرفه من العين بصفة مستمرة ويتم استبداله بسائل جديد. إذا لم تتم عملية صرف السائل بالسرعة الكافية، فإن الضغط داخل العين يرتفع وقد يؤدي في النهاية إلى تلف الإبصار (مرض يُسمى جلوكوما). يزاول جانفورت مفعوله من خلال تقليل إنتاج السائل كما أنه يعمل أيضاً على زيادة الكمية المنصرفة من السائل. هذا يقلل الضغط داخل العين.</p><p dir="RTL">يتم استعمال قطرة العين جانفورت لعلاج الضغط المرتفع في العين في البالغين، بما فيهم المسنين. هذا الضغط المرتفع قد يؤدي إلى الجلوكوما. سوف ينصحك طبيبك باستعمال جانفورت عندما تكون القطرات العينية الأخرى المحتوية على حاصرات البيتا أو على محاكيات البروستاجلاندين غير كافية بمفردها لعلاج الحالة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل جانفورت قطرة للعين، محلول</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أرجية (حساسية) تجاه بيماتوبروست، أو تيمولول، أو حاصرات البيتا، أو أي من المكونات الأخرى الموجودة في جانفورت (المذكورة في البند 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك الآن أو إذا كان قد حدث لديك في الماضي، مشاكل تنفسية مثل الربو أو الالتهاب الشُعبي الانسدادي المزمن الشديد (مرض رئوي شديد قد يُسبب الأزيز، وصعوبة التنفس و/أو سعال طويل الأجل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل في القلب مثل بطء القلب، أو إحصار القلب، أو الفشل القلبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">قبل أن تستعمل هذا الدواء، أخبر طبيبك إذا كان لديك الآن أو إذا كان قد حدث لديك في الماضي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض قلبي تاجي (الأعراض يمكن أن تشمل حدوث ألم أو ضيق في الصدر، انقطاع التنفس، أو اختناق)، فشل قلبي، انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في سرعة القلب مثلاً في شكل بطء ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس، ربو أو مرض رئوي انسدادي مزمن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض ضعف الدورة الدموية (مثل مرض رينود أو متلازمة رينود)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية حيث أن تيمولول قد يحجب علامات وأعراض المرض الدرقي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكر حيث أن تيمولول قد يحجب علامات وأعراض نقص السكر في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الأرجية الشديدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد أو الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في سطح العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال إحدى الطبقات داخل مُقلة العين بعد عملية جراحية لخفض الضغط داخل العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عوامل المخاطرة المعروفة المتعلقة بالوذمة البُقعية (تورم الشبكية داخل العين بما يؤدي إلى تدهور الإبصار)، مثلاً جراحة المياه البيضاء.</p><p dir="RTL">قبل التخدير لإجراء عملية جراحية أخبر طبيبك بأنك تستعمل جانفورت، حيث أن تيمولول قد يغير آثار بعض الأدوية التي تُستخدَم أثناء التخدير.</p><p dir="RTL">قد يؤدي جانفورت إلى نمو الأهداب (الرموش) وتحول لونها إلى اللون الداكن، وقد يجعل الجلد حول الجفون يتحول إلى اللون الداكن أيضاً. قد يتحول لون القزحية أيضاً إلى اللون الداكن بمرور الزمن. هذه التغيرات قد تكون مستديمة. وقد يكون التغير أكثر وضوحاً إذا كنت تعالج عيناً واحدة فقط. قد يسبب جانفورت نمو الشعر اذا لامس سطح الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي استعمال جانفورت في الأطفال والمراهقين تحت 18 سنة من العمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وجانفورت</strong></p><p dir="RTL">من الممكن أن يؤثر جانفورت أو يتأثر بالأدوية الأخرى التي تستعملها، بما في ذلك سائر قطرات العين التي تستعملها لعلاج الجلوكوما. برجاء إبلاغ طبيبك أو الصيدلي إذا كنت تستعمل حالياً، أو إذا كنت قد استعملت منذ فترة قصيرة، أو من الممكن أن تستعمل أي أدوية أخرى. أخبر طبيبك إذا كنت تستعمل أو تنوي أن تستعمل أدوية لخفض ضغط الدم، أو أدوية للقلب، أو أدوية لعلاج مرض السكر، أو كينيدين (يُستعمَل لعلاج أمراض القلب وبعض أنواع الملاريا)، أو أدوية لعلاج الاكتئاب مثل فلوكسيتين وباروكسيتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، أو إذا ظننتِ أنك قد تكوني حاملاً، أو إذا كنتِ تخططين للحمل، استشيري طبيبك أو الصيدلي قبل استعمال هذا الدواء. لا تستعملي جانفورت إذا كنتِ حاملاً ما لم يوصي طبيبك بذلك.</p><p dir="RTL">لا تستعملي جانفورت إذا كنتِ مرضعة. فإن تيمولول يمكن أن ينفذ إلى لبن الثدي. استشيري طبيبك قبل استعمال أي دواء أثناء الإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارة وتشغيل الآلات</strong></p><p dir="RTL">قد يؤدي جانفورت إلى حدوث غشاوة في الإبصار في بعض المرضى. امتنع عن قيادة السيارة أو تشغيل الآلات إلى أن تزول الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي جانفورت على كلوريد البنزالكونيوم.</strong></p><p dir="RTL">&nbsp;يحتوي جانفورت على مادة حافظة تُسمى كلوريد البنزالكونيوم.</p><p dir="RTL">هذا الدواء &nbsp;يحتوى على 0.15 &nbsp;مجم من كلوريد البنزالكونيوم فى كل 3 مل من المحلول التى تعادل 0.05 مجم /مل.كلوريد البنزالكونيوم يمكن امتصاصه بواسطه العدسات اللاصقه اللينه وقد يؤدى ذلك الى تغير لون العدسات اللاصقة لذلك يجب ازالة العدسات اللاصقه&nbsp; قبل استعمال هذا الدواء وتركها جانبا لمدة 15 دقيقة بعد استعمال الدواء .</p><p dir="RTL">قد يسبب&nbsp; كلوريد البنزالكونيوم تهيج العين خاصة ان كنت تعانى من جفاف العين او لديك مشاكل فى القرنية )الطبقة الشفافة السطحية للعين ), اذا شعرت بشعور غير طبيعى بالعين او حرقان او الم بالعين بعد استعمال الدواء اتصل بطبيبك مباشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزم دائماً بتعليمات طبيبك أو الصيدلي عند استعمال جانفورت. استشر طبيبك أو الصيدلي إذا كنت غير متأكد من طريقة الاستعمال.</p><p dir="RTL">الجرعة المعتادة هي نقطة واحدة مرة واحدة في اليوم، سواء في الصباح أو المساء في كل عين تحتاج لعلاج. استعمل القطرة في نفس الموعد كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات خاصة بالاستعمال</strong></p><p dir="RTL">لا تستعمل الزجاجة إذا كانت سدادة الأمان على عنق الزجاجة مكسورة قبل أول استعمال.</p><p><img alt="" width="540" height="226" src="data:image/png;base64,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" /></p><p>5.<img alt="" width="390" height="161" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p dir="RTL">- اغسل يديك. أمل رأسك إلى الخلف وانظر إلى السقف.</p><p dir="RTL">2- اسحب الجفن السفلي برفق إلى أسفل بحيث يتكون جيب صغير.</p><p dir="RTL">3- اقلب الزجاجة بحيث تتجه إلى أسفل، واضغط عليها بحيث تنزلق نقطة إلى كل عين تحتاج لعلاج.</p><p dir="RTL">4- اترك الجفن السفلي، وأغمض عينك.</p><p dir="RTL">5- مع الاستمرار في إغماض العين، اضغط بإصبعك على زاوية العين المغمضة (مكان التقاء العين بالأنف) لمدة دقيقتين. هذا سيساعد في منع جانفورت من الوصول إلى بقية جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تدخل النقطة في عينك، حاول مرة أخرى.</p><p dir="RTL">لتجنب التلوث، لا تدع طرف الزجاجة يلمس عينك أو أي شيء آخر. أعد الغطاء وأغلق الزجاجة فوراً بعد استعمالها.</p><p dir="RTL">إذا كنت تستعمل جانفورت مع دواء آخر للعين، يجب أن تمر 5 دقائق على الأقل بين تقطير جانفورت وبين وضع الدواء الآخر. إذا كنت تستعمل أي مرهم أو جِل للعين فليكن في النهاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استعملت كمية أكبر مما ينبغي من جانفورت</p><p dir="RTL">إذا استعملت كمية أكبر مما ينبغي من جانفورت، من المُستبعد أن يسبب ذلك أي أذى خطير. استعمل الجرعة التالية في موعدها كالمعتاد. إذا شعرت بالقلق ناقش الأمر مع طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت أن تستعمل جانفورت</p><p dir="RTL">إذا نسيت أن تستعمل جانفورت، استعمل نقطة واحدة بمجرد أن تتذكره، ثم ارجع إلى نظامك المعتاد. لا تستعمل جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن استعمال جانفورت</p><p dir="RTL">يجب استعمال جانفورت يومياً لكي يزاول مفعوله بشكل صحيح.</p><p dir="RTL">إذا كان لديك مزيد من الأسئلة عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي جانفورت إلى حدوث آثار جانبية، وإن كانت لا تحدث لجميع الأشخاص. يمكنك عادةً الاستمرار في استعمال القطرة، ما لم تكن الآثار الجانبية خطيرة. إذا شعرت بالقلق ناقش الأمر مع طبيبك أو الصيدلي. لا توقف استعمال جانفورت بدون أن تتحدث مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث الآثار الجانبية التالية في العين أثناء استعمال جانفورت. )و/أو قنينة للاستعمال لمرة واحدة(.</p><p dir="RTL">)</p><p dir="RTL">آثار جانبية شائعة جداً:</p><p dir="RTL">قد تؤثر في أكثر من 1 من بين 10 مستخدمين</p><p dir="RTL"><u>التأثير في العين</u></p><p dir="RTL">احمرار</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية شائعة:</p><p dir="RTL">قد تؤثر في1 الى9 أكثر من بين 100 مستخدم</p><p dir="RTL"><u>التأثير في العين</u></p><p dir="RTL">إحساس حارق، حكة، وخز، تهيج الملتحمة (النظر من خلال طبقة من العين( حساسية للضوء، ألم العين، لزوجة العينين، جفاف العينين، الإحساس بوجود شيء داخل العين، تشققات صغيرة على سطح العين مع أو بدون التهاب، صعوبة في الإبصار بوضوح، احمرار وحكة في الجفون، نمو الشعر حول العين ، تحول لون الجفون إلى اللون الداكن، تحول لون الجلد المحيط بالعينين إلى اللون الداكن، ازدياد طول الرموش، تهيج العين، عيون دامعة، انتفاخ الجفون، ضعف الابصار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التأثير على أجزاء الجسم الأخرى</u></p><p dir="RTL">رشح من الأنف ، صداع،</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية غير شائعة:</p><p dir="RTL">قد تؤثر في1 الى9 أكثر من بين 1000 مستخدم</p><p dir="RTL"><u>التأثير في العين</u></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير طبيعي في العين، التهاب القزحية، تورم الملتحمة (الطبقة الشفافة التي تغطي سطح العين)، ألم في الجفون، عيون مُجهَدة، نمو الأهداب إلى الداخل، تحول لون القزحية إلى اللون الداكن، العين تبدو غائرة، تدلي الجفن، تقلص الجفن (الابتعاد عن سطح العين مما يؤدي إلى إغلاق غير كامل للجفون)، شد جلد الجفون، اسوداد الرموش.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التأثير على أجزاء الجسم الأخرى</u></p><p dir="RTL"><u>ضيق في التنفس</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية غير معروف التكرار:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><u>التأثير في العين</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">وذمة بقعية كيسانية (تورم الشبكية داخل العين مما يؤدي إلى تدهور الإبصار)، انتفاخ العين، رؤية غيرواضحة,انزعاج بصرى.</p><p dir="RTL"><u>التأثير على أجزاء الجسم الأخرى</u></p><p dir="RTL">صعوبة في التنفس / الأزيز، أعراض الحساسية (تورم، احمرار في العين وطفح في الجلد)، التغيرات في احساس التذوق، دوار ,تباطؤ معدل ضربات القلب،، ارتفاع ضغط الدم , صعوبة في النوم، كوابيس، الربو، فقدان الشعر، تلون بالجلد(المحيط بالعين) ,التعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">شوهدت آثار جانبية إضافية في المرضى الذين يستخدمون قطرات للعين تحتوي على تيمولول أو بيماتوبروست وبالتالي من الممكن أن تحدث مع جانفورت. شأنه شأن سائر الأدوية التي تُستعمَل في العين، فإن تيمولول يُمتَص إلى الدم. وهذا قد يؤدي إلى حدوث آثار جانبية مماثلة لما يحدث مع حاصرات البيتا التي تؤخذ &quot;بالحقن في الوريد&quot; و/أو &quot;عن طريق الفم&quot;. يكون احتمال حدوث آثار جانبية عقب استعمال قطرة العين أقل مما يحدث عند إعطاء الأدوية على سبيل المثال، عن طريق الفم أو بالحقن. الآثار الجانبية المذكورة تشمل التفاعلات التي شوهدت مع بيماتوبروست و تيمولول عند استعمالها لعلاج أمراض العين:</p><p dir="RTL">&bull;&nbsp; تفاعلات أرجية شديدة مع تورم وصعوبة في التنفس مما قد يكون مهدداً للحياة.</p><p dir="RTL">&bull; &nbsp;نقص سكر الدم.</p><p dir="RTL">&bull;&nbsp; اكتئاب؛ فقدان الذاكرة الهلوسة.</p><p dir="RTL">&bull; إغماء؛ سكتة دماغية؛ نقص سريان الدم إلى الدماغ؛ اشتداد الوهن العضلي الوخيم (زيادة ضعف العضلات)؛ إحساس بالتنميل.</p><p dir="RTL">&bull; نقص الإحساس في سطح العين؛ ازدواج الرؤية؛ ارتخاء الجفن؛ انفصال إحدى الطبقات داخل مُقلة العين بعد عملية جراحية لخفض الضغط في العين؛ التهاب سطح العين، النزيف في الجزء الخلفي من العين (نزيف في شبكية العين)، التهاب داخل العين، زيادة الومض.</p><p dir="RTL">&bull; فشل قلبي؛ عدم انتظام أو توقف ضربات القلب ؛ بطء أو سرعة النبض؛ تراكم السوائل، أساساً الماء، في الجسم؛ ألم في الصدر.</p><p dir="RTL">&bull; انخفاض ضغط الدم؛ تورم أو برودة اليدين، والقدمين، والأطراف، بسبب تضيق الأوعية الدموية.</p><p dir="RTL">&bull; سعال، تفاقم الربو، تفاقم مرض الرئة&nbsp; والذي يسمى مرض الانسداد الرئوي المزمن</p><p dir="RTL">&bull; إسهال؛ ألم في البطن؛ غثيان وقيء؛ عُسر هضم؛ جفاف الفم.</p><p dir="RTL">&bull; رُقع حمراء متقشرة على الجلد؛ طفح جلدي.</p><p dir="RTL">&bull; ألم عضلي.</p><p dir="RTL">&bull; نقص الرغبة الجنسية؛ خلل في الوظيفة الجنسية.</p><p dir="RTL">&bull; ضعف.</p><p dir="RTL">&bull; زيادة في نتائج اختبار الدم التي تظهر كيف يعمل الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الأخرى التي أبلغت مع قطرات العين التي تحتوي على الفوسفات<br />&nbsp;</p><p dir="RTL">هذا الدواء يحتوى &nbsp;2.85 مجم فوسفات فى كل 3 مل من المحلول والتى تعادل 0.95 مجم/ مل .</p><p dir="RTL">اذا كنت تعانى&nbsp; من تلف شديد فى الطبقة الشفافة الامامية للعين (القرنية), قد يسبب الفوسفات فى حالات نادرة من بقع غائمة على القرنية نتيجة تراكم الكالسيوم اثناء العلاج .</p><p dir="RTL">الابلاغ عن الاثار الجانبية:</p><p dir="RTL">إذا زادت أي من التأثيرات الجانبية&nbsp; تحدث إلى طبيبك أو الصيدلي أو الممرضة. وهذا يشمل أي تأثيرات جانبية ممكنة ليست مذكورة في هذه النشرة</p><p dir="RTL">يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني<br />من خلال الابلاغ عن الآثار الجانبية يمكن أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ جانفورت بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">لا تستعمل جانفورت بعد تاريخ انتهاء الصلاحية المذكور على مُلصق الزجاجة وعلى العلبة الخارجية أمام العلامة &ldquo;EXP&rdquo;. تاريخ انتهاء الصلاحية يُشير إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يحفظ عند درجه حراره اقل من &nbsp;25 درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد فتح الزجاجة، قد يتعرَّض المحلول للتلوث، مما قد يسبب عدوى في العين. لذلك يجب التخلُّص من الزجاجة بعد 4 أسابيع من فتحها لأول مرة، حتى إذا تبقى بداخلها بعض المحلول. لمساعدتك على تذكر ذلك، اكتب تاريخ فتح الزجاجة في المسافة الخالية على العلبة.</p><p dir="RTL">لا ينبغي التخلص من أي أدوية بالقائها في مياه الصرف أو في القمامة المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم يعد لها استعمال. هذه الإجراءات ستساعد على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي بيماتوبروست 0.3 مجم/ ملليلتر وتيمولول 5 مجم/ ملليلتر بما يكافئ تيمولول ماليات 6.8 مجم/ ملليلتر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي كلوريد بنزالكونيوم (مادة حافظة)، كلوريد صوديوم، فوسفات صوديوم ثنائي القاعدة سباعي التميؤ، حمض سيتريك أحادي التميؤ، وماء منقى. قد يتم إضافة كميات صغيرة من حمض الهيدروكلوريك أو هيدروكسيد الصوديوم لضبط مستوى الأس الهيدروجيني (درجة الحموضة) للمحلول عند المستوى الصحيح.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جانفورت هو قطرة للعين في شكل محلول رائق، عديم اللون إلى أصفر باهت، في زجاجة بلاستيكية. تحتوي كل عبوة على 1 أو 3 زجاجات بلاستيكية، لكل منها غطاء لولبي. كل زجاجة ممتلئة إلى نصفها تقريباً، وتحتوي على 3 ملليلتر من المحلول، وهي كمية تكفي للاستخدام 4 أسابيع. ليس بالضرورة أن تكون جميع أحجام العبوات مطروحة في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">ألليرجان فارماسيوتيكالس أيرلندا</p><p dir="RTL">كاسلبار رود</p><p dir="RTL">وستبورت</p><p dir="RTL">كونتي مايو</p><p dir="RTL">أيرلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المسوقة</strong></p><p dir="RTL">أبفي دويتشلاند جي إم بي و شركاه كي جي</p><p dir="RTL">كنولستراسي</p><p dir="RTL">٦٧٠٦١ لوفيغسهافن</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت آخر مراجعة لهذه النشرة في  يناير 2022

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of solution contains 0.3 mg of bimatoprost and 5 mg of timolol (as 6.8 mg of timolol maleate).

Excipients with known effect
Each ml of solution contains 0.05 mg of benzalkonium chloride.

For  the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.

Colourless to slightly yellow solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Recommended dosage in adults (including older people)</em></p><p>The recommended dose is one drop of GANFORT in the affected eye(s) once daily, administered either in the morning or in the evening. It should be administered at the same time each day.</p><p>&nbsp;</p><p>Existing literature data for GANFORT suggest that evening dosing may be more effective in IOP lowering than morning dosing. However, consideration should be given to the likelihood of compliance when considering either morning or evening dosing (see section 5.1).</p><p>&nbsp;</p><p>If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>GANFORT has not been studied in patients with hepatic or renal impairment. Therefore caution should be used in treating such patients.&nbsp;</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of GANFORT in children aged 0 to 18 years has not been established. No data are available.</p><p><u>Method of administration</u></p><p>If more than one topical ophthalmic medicinal product is to be used, each one should be instilled at least 5 minutes apart.</p><p>&nbsp;</p><p>When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
-	Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
-	Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block, not controlled with pace-maker. Overt cardiac failure, cardiogenic shock.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like other topically applied ophthalmic medicinal products, the active substances (timolol/ bimatoprost) in GANFORT may be absorbed systemically. No enhancement of the systemic absorption of the individual active substances has been observed. Due to the beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions as seen with systemic beta-blockers may occur. Incidence of systemic&nbsp;ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>Patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&#39;s angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.</p><p>Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.</p><p><u>Vascular disorders</u></p><p>Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome) should be treated with caution.</p><p>&nbsp;</p><p><u>Respiratory disorders</u></p><p>Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.</p><p>&nbsp;</p><p>GANFORT should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.</p><p>&nbsp;</p><p><u>Endocrine disorders</u></p><p>Beta-adrenergic blocking medicinal products should be administered with caution in patients subject to spontaneous hypoglycemia or to patients with labile diabetes as beta‑blockers may mask the signs and symptoms of acute hypoglycemia.</p><p>&nbsp;</p><p>Beta-blockers may also mask the signs of hyperthyroidism.</p><p>&nbsp;</p><p><u>Corneal diseases</u></p><p>Ophthalmic &beta;-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.</p><p>&nbsp;</p><p><u>Other beta-blocking agents</u></p><p>The effect on intra-ocular pressure or the known effects of systemic beta‑blockade may be potentiated when timolol is given to the patients already receiving a systemic beta‑ blocking agent. The response of these patients should be closely observed. The use of two topical beta‑adrenergic blocking agents is not recommended (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Anaphylactic reactions</u></p><p>While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.</p><p>&nbsp;</p><p><u>Choroidal detachment</u></p><p>Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.</p><p>&nbsp;</p><p><u>Surgical anaesthesia</u></p><p>&beta;-blocking ophthalmological preparations may block systemic &beta;-agonist effects e.g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.</p><p>&nbsp;</p><p><u>Hepatic</u></p><p>In patients with a history of mild liver disease or abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin at baseline, bimatoprost had no adverse reactions on liver function over 24 months. There are no known adverse reactions of ocular timolol on liver function.</p><p>&nbsp;</p><p><u>Ocular </u></p><p>Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid or periocular skin and increased brown iris pigmentation since these have been observed during treatment with bimatoprost and GANFORT. Increased iris pigmentation is likely to be permanent, and may lead to differences in appearance between the eyes if only one eye is treated. After discontinuation of GANFORT, pigmentation of iris may be permanent. After 12 months treatment with GANFORT, the incidence of iris pigmentation was 0.2%. After 12 months treatment with bimatoprost eye drops alone, the incidence was 1.5% and did not increase following 3 years treatment. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The long term effects of increased iridial pigmentation are not known.&nbsp; Iris color changes seen with ophthalmic administration of bimatoprost may not be noticeable for several months to years. Neither nevi nor freckles of the iris appear to be affected by treatment. Periorbital tissue pigmentation has been reported to be reversible in some patients.</p><p>&nbsp;</p><p>Macular oedema, including cystoid macular oedema, has been reported with GANFORT. Therefore, GANFORT should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular oedema (e.g. intraocular surgery, retinal vein occlusions, ocular inflammatory disease and diabetic retinopathy). &nbsp;</p><p>GANFORT should be used with caution in patients with active intraocular inflammation (e.g. uveitis) because the inflammation may be exacerbated.</p><p>&nbsp;</p><p><u>Skin </u></p><p>There is a potential for hair growth to occur in areas where GANFORT solution comes repeatedly in contact with the skin surface. Thus, it is important to apply GANFORT as instructed and avoid it running onto the cheek or other skin areas.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>The preservative in GANFORT, benzalkonium chloride, may cause eye irritation. Contact lenses must be removed prior to application, with at least a 15-minute wait before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.&nbsp; Contact with soft contact lenses must be avoided.</p><p>&nbsp;</p><p>Benzalkonium chloride has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Therefore monitoring is required with frequent or prolonged use of GANFORT in dry eye patients or where the cornea is compromised.</p><p>&nbsp;</p><p><u>Other conditions</u></p><p>GANFORT has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma.</p><p>&nbsp;</p><p>In studies of bimatoprost 0.3 mg/ml in patients with glaucoma or ocular hypertension, it has been shown that more frequent exposure of the eye to more than 1 dose of bimatoprost daily may decrease the IOP-lowering effect. Patients using GANFORT with other prostaglandin analogues should be monitored for changes to their intraocular pressure.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been performed with the bimatoprost / timolol fixed combination.</p><p>&nbsp;</p><p>There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when&nbsp; ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, guanethidine, beta-adrenergic blocking agents, parasympathomimetics, anti-arrhythmics (including amiodarone) and digitalis glycosides.</p><p>&nbsp;</p><p>Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.</p><p>&nbsp;</p><p>Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of the bimatoprost / timolol fixed combination in pregnant women. GANFORT should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p><em>Bimatoprost</em></p><p>No adequate clinical data in exposed pregnancies are available. Animal studies have shown reproductive toxicity at high maternotoxic doses (see section 5.3).</p><p>&nbsp;</p><p><em>Timolol</em></p><p>Epidemiological studies have not revealed malformative effects but shown a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If GANFORT is administered until delivery, the neonate should be carefully monitored during the first days of life. Animal studies with timolol have shown reproductive toxicity at doses significantly higher than would be used in clinical practice (see section 5.3).&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><em>Timolol </em></p><p>Beta-blockers are excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p><em>Bimatoprost</em></p><p>It is not known if bimatoprost is excreted in human breast milk but it is excreted in the milk of the lactating rat. GANFORT should not be used by breast-feeding women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effects of GANFORT on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GANFORT has negligible influence on the ability to drive and use machines. As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>GANFORT</u></p><p><em>Summary of the safety profile</em></p><p>The adverse reactions reported in clinical studies using GANFORT were limited to those earlier reported for either of the single active substances bimatoprost and timolol. No new adverse reactions specific for GANFORT have been observed in clinical studies.</p><p>&nbsp;</p><p>The majority of adverse reactions reported in clinical studies using GANFORT were ocular, mild in severity and none were serious. Based on 12-month clinical data, the most commonly reported adverse reaction was conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in approximately 26% of patients and led to discontinuation in 1.5% of patients.</p><p>&nbsp;</p><p><em>Tabulated list of adverse reactions</em></p><p>Table 1 presents the&nbsp; adverse reactions that have been reported during clinical studies with all GANFORT</p><p>formulations (multi-dose and single-dose) &nbsp;(within each frequency grouping, adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.</p><p>&nbsp;</p><p>The frequency of possible adverse reactions listed below is defined using the following convention:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;&ge;1/10</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&ge;1/100 to &lt;1/10</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&ge;1/1,000 to &lt;1/100</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&ge;1/10,000 to &lt;1/1,000</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&lt;1/10,000</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Frequency cannot be estimated from available data</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 1</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including signs or symptoms of allergic dermatitis,&nbsp; angioedema, eye allergy</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>insomnia<sup>2</sup>, nightmare<sup>2</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>dysgeusia<sup>2,</sup> dizziness</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>conjunctival hyperaemia.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>punctuate keratitis, corneal erosion<sup>2</sup>, burning sensation<sup>2</sup>, conjunctival irritation<sup>1</sup>, eye pruritus, stinging sensation in the eye<sup>2</sup>, foreign body sensation, dry eye, erythema of eyelid, eye pain, photophobia, eye discharge<sup>,</sup>, visual disturbance<sup>2</sup>, eyelid pruritus, visual acuity worsened<sup>2</sup>, blepharitis<sup>2</sup>,&nbsp; eyelid oedema, eye irritation, lacrimation increase, growth of eyelashes.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>iritis<sup>2</sup>, conjunctival oedema<sup>2</sup>, eyelid pain<sup>2</sup>, abnormal sensation in the eye<sup>1</sup>, asthenopia, trichiasis<sup>2</sup>, iris hyperpigmentation<sup>2</sup>,&nbsp; periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus, eyelid ptosis, enophthalmos, lagophthalmos and eyelid retraction<sup>1&amp;2</sup>, eyelash discolouration (darkening)<sup>1</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>cystoid macular oedema<sup>2</sup>, eye swelling, vision blurred<sup>2,</sup> ocular discomfort</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rhinitis<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>bronchospasm (predominantly in patients with pre-existing bronchospastic disease)<sup> 2</sup>, asthma</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>blepharal pigmentation<sup>2</sup>, hirsutism<sup>2</sup>, skin hyperpigmentation (periocular).</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>alopecia<sup>,</sup> skin discolouration (periocular)</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr></tbody></table><p><sup>1</sup>adverse reactions only observed with Ganfort single-dose formulation</p><p><sup>2</sup>adverse reactions only observed with Ganfort multi-dose formulation</p><p><em>&nbsp;</em></p><p>Like other topically applied ophthalmic drugs, GANFORT (bimatoprost/timolol) is absorbed into the systemic circulation. Absorption of timolol may cause similar undesirable effects as seen with systemic beta-blocking agents.&nbsp; The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>Additional adverse reactions that have been seen with either of the active substances (bimatoprost or timolol), and may potentially occur also with GANFORT are listed below in Table 2</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>systemic allergic reactions including anaphylaxis<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>hypoglycaemia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>depression<sup>1</sup>, memory loss<sup>1</sup>, hallucination<sup>1</sup><sup>.</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>syncope<sup>1</sup>, cerebrovascular accident<sup>1</sup>, increase in signs and symptoms of myasthenia gravis<sup>1</sup>, paraesthesia<sup>1</sup>, cerebral ischaemia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>decreased corneal sensitivity<sup>1</sup>, diplopia<sup>1</sup>, ptosis<sup>1</sup>, choroidal detachment following filtration surgery (see section 4.4)<sup>1</sup>,&nbsp; keratitis<sup>1</sup>, blepharospasm<sup>2</sup>, retinal haemorrhage<sup>2</sup>, uveitis<sup>2</sup>,</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorder</em></p></td><td style="vertical-align:top"><p>atrioventricular block<sup>1</sup>, cardiac arrest<sup>1</sup>, arrhythmia<sup>1</sup>, cardiac failure<sup>1</sup>, congestive heart failure<sup>1</sup>, chest pain<sup>1</sup>, palpitations<sup>1</sup>, oedema<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>hypotension<sup>1</sup>,Raynaud&rsquo;s phenomenon<sup>1</sup>, cold hands and feet<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Asthma exacerbation<sup>2</sup>, COPD exacerbation<sup>2</sup>, cough<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>nausea<sup>1,2</sup>, diarrhoea<sup>1</sup>, dyspepsia<sup>1</sup>, dry mouth<sup>1</sup>, abdominal pain<sup>1</sup>, vomiting<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>psoriasiform rash<sup>1</sup> or exacerbation of psoriasis<sup>1</sup>, skin rash<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>myalgia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top"><p>sexual dysfunction<sup>1</sup>, decreased libido<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>asthenia<sup>1,2</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top"><p>liver function tests (LFT) abnormal<sup>2</sup></p></td></tr></tbody></table><p><sup>1</sup> adverse reactions observed with Timolol</p><p><sup>2</sup> adverse reactions observed with Bimatoprost</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Adverse reactions reported in phosphate containing eye drops</u></p><p>&nbsp;</p><p>Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.</p><p><em><u>&nbsp;</u></em></p><p><u>Reporting of suspected adverse reactions</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:-</p><p>Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A topical overdose with GANFORT is not likely to occur or to be associated with toxicity.</p><p>&nbsp;</p><p><u>Bimatoprost</u></p><p>If GANFORT is accidentally ingested, the following information may be useful: in two-week oral rat and mouse studies, doses of bimatoprost up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m<sup>2</sup> is at least 70-times higher than the accidental dose of one bottle of GANFORT in a 10 kg child.</p><p>&nbsp;</p><p><u>Timolol</u></p><p>Symptoms of systemic timolol overdose include: bradycardia, hypotension, bronchospasm, headache, dizziness, shortness of breath, and cardiac arrest.&nbsp; A study of patients with renal failure showed that timolol did not dialyse readily.</p><p>&nbsp;</p><p>If overdose occurs treatment should be symptomatic and supportive.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmological,&ndash; beta-blocking agents &ndash; ATC code: S01ED51</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>GANFORT consists of two active substances: bimatoprost and timolol. These two components decrease elevated intraocular pressure (IOP) by complementary mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone. GANFORT has a rapid onset of action.</p><p>&nbsp;</p><p>Bimatoprost is a potent ocular hypotensive active substance .&nbsp; It is a synthetic prostamide, structurally related to prostaglandin F<sub>2</sub><sub>a</sub> (PGF<sub>2</sub><sub>a</sub>) that does not act through any known prostaglandin receptors.&nbsp; Bimatoprost selectively mimics the effects of newly discovered biosynthesised substances called prostamides.&nbsp; The prostamide receptor, however, has not yet been structurally identified.&nbsp; The mechanism of action by which bimatoprost reduces intraocular pressure in man is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.</p><p>&nbsp;</p><p>Timolol is a beta<sub>1</sub> and beta<sub>2</sub> non-selective adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane‑stabilising) activity.&nbsp; Timolol lowers IOP by reducing aqueous humour formation.&nbsp; The precise mechanism of action is not clearly established, but inhibition of the increased cyclic AMP synthesis caused by endogenous beta-adrenergic stimulation is probable.</p><p>&nbsp;</p><p><u>Clinical effects</u></p><p>The IOP-lowering effect of GANFORT is non-inferior to that achieved by adjunctive therapy of bimatoprost (once daily) and timolol (twice daily).</p><p>&nbsp;</p><p>Existing literature data for GANFORT suggest that evening dosing may be more effective in IOP lowering than morning dosing. However, consideration should be given to the likelihood of compliance when considering either morning or evening dosing.</p><p><u>Paediatric population</u></p><p>The safety and efficacy of GANFORT in children aged 0 to 18 years has not been established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>GANFORT medicinal product</u></p><p>Plasma bimatoprost and timolol concentrations were determined in a crossover study comparing the monotherapy treatments to GANFORT treatment in healthy subjects.&nbsp; Systemic absorption of the individual components was minimal and not affected by co-administration in a single formulation.</p><p>&nbsp;</p><p>In two 12-month studies where systemic absorption was measured, no accumulation was observed with either of the individual components.</p><p><em>&nbsp;</em></p><p><u>Bimatoprost</u></p><p>Bimatoprost penetrates the human cornea and sclera well <em>in vitro</em>.&nbsp; After ocular administration, the systemic exposure of bimatoprost is very low with no accumulation over time. After once daily ocular administration of one drop of 0.03% bimatoprost to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing.&nbsp; Mean C<sub>max</sub> and AUC <sub>0-24hrs</sub> values were similar on days 7 and 14 at approximately 0.08 ng/ml and 0.09&nbsp;ng&middot;hr/ml respectively, indicating that a steady drug concentration was reached during the first week of ocular dosing.</p><p>&nbsp;</p><p>Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 1/kg. In human blood, bimatoprost resides mainly in the plasma. The plasma protein binding of bimatoprost is approximately 88%.</p><p>&nbsp;</p><p>Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.</p><p>&nbsp;</p><p>Bimatoprost is eliminated primarily by renal excretion, up to 67% of an intravenous dose administered to healthy volunteers was excreted in the urine, 25% of the dose was excreted via the faeces. The elimination half-life, determined after intravenous administration, was approximately 45 minutes; the total blood clearance was 1.5 1/hr/kg.</p><p>&nbsp;</p><p><u>Characteristics in older people</u></p><p>After twice daily dosing, the mean AUC <sub>0-24hrs</sub> value of 0.0634 ng&middot;hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng&middot;hr/ml in young healthy adults. However, this finding is not clinically relevant as systemic exposure for both elderly and young subjects remained very low from ocular dosing. There was no accumulation of bimatoprost in the blood over time and the safety profile was similar in elderly and young patients.</p><p>&nbsp;</p><p><u>Timolol</u></p><p>After ocular administration of a 0.5% eye drops solution in humans undergoing cataract surgery, peak timolol concentration was 898&nbsp;ng/ml in the aqueous humour at one hour post-dose.&nbsp; Part of the dose is absorbed systemically where it is extensively metabolised in the liver. The half-life of timolol in plasma is about 4 to 6 hours.&nbsp; Timolol is partially metabolised by the liver with timolol and its metabolites excreted by the kidney.&nbsp; Timolol is not extensively bound to plasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>GANFORT medicinal product</u></p><p>Repeated dose ocular toxicity studies on GANFORT showed no special hazard for humans. The ocular and systemic safety profile of the individual components is well established.</p><p>&nbsp;</p><p><u>Bimatoprost</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, carcinogenic potential. Studies in rodents produced species-specific abortion at systemic exposure levels 33- to 97-times that achieved in humans after ocular administration.</p><p><em>&nbsp;</em></p><p>Monkeys administered ocular bimatoprost concentrations of &sup3;0.03% daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure. The increased iris pigmentation appears to be caused by increased stimulation of melanin production in melanocytes and not by an increase in melanocyte number. No functional or microscopic changes related to the periocular effects have been observed, and the mechanism of action for the periocular changes is unknown.</p><p>&nbsp;</p><p><u>Timolol</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzalkonium chloride</p><p>Sodium chloride</p><p>Sodium phosphate dibasic heptahydrate</p><p>Citric acid monohydrate</p><p>Hydrochloric acid or sodium hydroxide (to adjust pH)</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years

Chemical and physical in-use stability has been demonstrated for 28 days at 25°C.

From a microbiological point of view, the in-use storage times and conditions are the responsibility of the user and would normally not be longer than 28 days at 25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at or below 25&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White opaque low-density polyethylene bottles with polystyrene screw cap. Each bottle has a fill volume of 3 ml.</p><p>&nbsp;</p><p>The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>